

ASX/Media Release

**Change of Company Secretary /
Change of Registered Office**

06 March 2007, Perth: The Board of Directors of EQiTX Limited (ASX:EQX) today announce that John Rawlings has resigned as Company Secretary and he will be replaced by Scott Mison.

The Board would like to thank Mr Rawlings for his contribution to the Company over the term of his tenure and wish him all the best in the next phase of his career.

Please also be advised that the Registered Office has changed to the following address:

Level 34, Exchange Plaza
2 The Esplanade
Perth WA 6000

ENDS

Shareholder Inquiries:

Geoff Gander
Executive Chairman
EQiTX Limited
0417 914 137

About EQiTX (www.EQiTX.com)

EQiTX Limited (ASX: EQX) is a publicly listed Australian biotechnology company with interests in the areas of chronic diseases and age-related conditions. EQiTX is developing a portfolio of technologies to a stage where they will be of commercial interest to multinational pharmaceutical and biotechnology companies. The company's two main programs are the ZingoTX project to develop pharmacologically active compounds for pain management, and the VacTX project to develop and commercialise novel synthetic immunotherapeutics against a range of human conditions, including infectious diseases, cancer, allergies and autoimmune diseases.

EQiTX Limited

Level 34, Exchange Plaza
2 The Esplanade
Perth WA 6000
Phone (+61 8) 9421 2111
Fax: (+61 8) 9421 2100

Email: info@eqitx.com
www.eqitx.com

ABN: 50 009 188 694